Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of BNT324 versus docetaxel plus prednisone/prednisolone in metastatic castration-resistant prostate cancer
2025-524445-27-00Phase 3Authorised
- Sponsor
- BioNTech SE
- Start
- Oct 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial of db-1311 in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by BioNTech SE. Primary endpoints: Radiographic progression-free survival and Overall survival. Planned start Oct 2026; status: authorised.
02
Drugs
db-1311
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2025-524445-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524445-27-00.